Black Creek Investment Management Inc. Grows Holdings in Grifols, S.A. (NASDAQ:GRFS)

Black Creek Investment Management Inc. increased its stake in Grifols, S.A. (NASDAQ:GRFS) by 7.7% in the second quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund owned 12,339,314 shares of the biotechnology company’s stock after buying an additional 881,155 shares during the period. Grifols comprises about 2.9% of Black Creek Investment Management Inc.’s investment portfolio, making the stock its 12th largest position. Black Creek Investment Management Inc.’s holdings in Grifols were worth $77,799,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other large investors have also recently added to or reduced their stakes in GRFS. Norges Bank acquired a new position in Grifols in the fourth quarter worth about $26,137,000. Sei Investments Co. increased its holdings in shares of Grifols by 5.3% in the 1st quarter. Sei Investments Co. now owns 2,109,416 shares of the biotechnology company’s stock valued at $14,091,000 after acquiring an additional 107,000 shares during the last quarter. Team Hewins LLC raised its position in shares of Grifols by 11.8% during the 1st quarter. Team Hewins LLC now owns 40,818 shares of the biotechnology company’s stock valued at $273,000 after acquiring an additional 4,324 shares in the last quarter. Hantz Financial Services Inc. bought a new position in Grifols during the second quarter worth $1,235,000. Finally, Morningstar Investment Services LLC acquired a new position in Grifols in the fourth quarter worth $186,000.

Grifols Price Performance

Shares of NASDAQ:GRFS opened at $9.26 on Monday. The company’s fifty day moving average is $8.12 and its two-hundred day moving average is $7.27. The company has a debt-to-equity ratio of 1.06, a current ratio of 1.68 and a quick ratio of 0.80. Grifols, S.A. has a 1-year low of $5.30 and a 1-year high of $12.15.

Grifols (NASDAQ:GRFS) last released its quarterly earnings data on Tuesday, July 30th. The biotechnology company reported $0.02 earnings per share for the quarter, missing the consensus estimate of $0.23 by ($0.21). Grifols had a return on equity of 1.73% and a net margin of 0.90%. The business had revenue of $1.96 billion for the quarter. Equities research analysts forecast that Grifols, S.A. will post 0.79 EPS for the current fiscal year.

Grifols Company Profile

Grifols, SA operates as a plasma therapeutic company in Spain, the United States, Canada, and internationally. The company provides immunoglobulin to treat immunodeficiencies; albumin used to restore circulatory volume and protein loss in pathophysiological conditions, such as liver cirrhosis, cardiocirculatory failure, trauma and severe burns; alpha-1 proteinase inhibitor, a plasma protein, used to treat a genetic disease known as alpha-1; factorVIII/von Willerbrand factor and factor IX, clotting factors for the treatment of hemophilia A and von Willebrand’s disease, as well as hemophilia B; antithrombin III to treat hereditary antithrombin deficiency; Fostamatinib, a spleen tyrosine kinase inhibitor; combination of fibrinogen and enzyme thrombin that acts as a biological sealant to control surgical bleeding; and plasma exchange with albumin used to treat Alzheimer’s disease.